European VC Funds

Angeleno Group, founded in 2001 and based in Los Angeles, is a venture capital firm specializing in growth capital for next-generation clean energy and climate solutions companies. With a strategic focus on sectors such as renewable energy, energy storage, sustainable mobility, and carbon mitigation, Angeleno Group aims to address critical global challenges posed by climate change. The firm leverages its extensive industry experience and longstanding relationships to support high-growth, innovative businesses. Angeleno Group invests opportunistically, typically deploying between $10 million and $30 million per opportunity, and focuses on companies with proven technologies and established customer traction. Their portfolio includes a diverse array of companies such as Fictiv, Span, and Anza RE, highlighting their commitment to fostering sustainable and transformative technologies. Angeleno Group's investment strategy is deeply rooted in creating value through active engagement with portfolio companies, providing support in product development, business strategy, sales, and corporate finance. The firm's approach is sector-focused, research-driven, and designed to build a diversified and high-return portfolio.

AngeliCo Ventures is a London-based venture capital firm and investment banking boutique founded in 2008. The firm specializes in healthcare, life sciences, and technology investments, targeting seed to growth-stage companies. AngeliCo Ventures focuses on sectors including digital health, therapeutics, diagnostics, medical devices, robotics, clean energy, and alternative care. The firm is known for its integrated strategy and investment banking solutions, offering services such as capital markets, mergers and acquisitions, strategic advisory, and research. AngeliCo Ventures prides itself on its extensive experience, having completed over $1.6 billion in transactions and raising $465 million for clients. Their approach emphasizes a strong relationship with research institutes and universities, providing early insights into high-potential discoveries. This connection helps AngeliCo Ventures to identify and support promising investment opportunities, guiding companies from inception through various stages of financing and strategic development.

Angelini Ventures is the corporate venture capital arm of Angelini Industries, founded in 2021 and headquartered in Rome, Italy. With a capital commitment of €300 million, Angelini Ventures focuses on early-stage investments in biotechnology, digital health, and life sciences. The firm aims to leverage technology to improve healthcare, reshape patient journeys, and address unmet needs in vulnerable populations. The firm has made significant investments globally, including in Europe, North America, and Israel, with a particular emphasis on brain health and consumer segments such as women, children, and the elderly. Notable portfolio companies include Pretzel Therapeutics, Argobio, Serenis, and Nouscom. Angelini Ventures is led by CEO Paolo Di Giorgio, who has extensive experience in the pharmaceutical and investment sectors. The team includes experts such as Elia Stupka, Managing Director, and Gabriela Manrique, Partner, among others, spread across major innovation hubs globally​.

Angelize is a Berlin-based platform designed for experienced founders across Europe to engage in angel investing. Its mission is to enable successful entrepreneurs to give back to the startup community by investing in the next generation of founders. By fostering a collaborative environment, Angelize helps these "founder-angels" remain active and relevant in the tech ecosystem. The platform simplifies the investment process by providing back-office support, making it easier for founders to focus on mentoring and guiding emerging startups. The program targets founders who have "earned their wings" and are looking for ways to support and mentor other entrepreneurs. Through Angelize, they gain access to a network of like-minded peers and promising startups, creating valuable opportunities for learning, growth, and meaningful impact. With a strong focus on fostering connections across the European tech landscape, Angelize is not just about financial investment but about building long-term relationships between seasoned founders and up-and-coming companies. Angelize stands out by combining financial backing with hands-on mentorship, ensuring that startups not only receive capital but also benefit from the extensive experience and insights of their investors. By bridging the gap between successful founders and new startups, Angelize plays a crucial role in supporting the entrepreneurial ecosystem across Europe.

Angels Santé, established in 2008 and based in Paris, is the largest healthcare-focused business angel network in Europe. It supports early-stage startups in the Biotech, Medtech, and Digital Health sectors, helping bring innovative solutions to market that benefit patients. With over 100 investments made since its inception, the organization fosters partnerships between entrepreneurs and healthcare professionals, providing not only capital but also deep industry expertise in clinical, regulatory, and scientific domains. Each year, Angels Santé finances 10-15 deals, with a focus on Europe, but its reach extends globally through partnerships with organizations like EBAN and Business Angels Europe. This international collaboration allows Angels Santé to facilitate cross-border investments and provide startups with access to a broader market. The network emphasizes a hands-on approach, guiding startups through the complexities of the healthcare landscape by offering mentorship and connections to relevant stakeholders. Notable figures such as Eric Garnier, the president, emphasize the critical role that healthcare innovation plays in solving modern challenges. Furthermore, their US branch, based in Boston, extends opportunities for French-speaking investors in the United States to support healthcare startups with global aspirations. Angels Santé is not just about funding; it's about building a community dedicated to advancing healthcare through innovation, with a long-term commitment to improving patient outcomes and supporting the growth of impactful healthcare companies.

Anglo Scientific is a venture capital firm that provides management and back-office services to high-tech startups, with a particular focus on artificial intelligence projects since its restructuring in November 2020. The firm, headquartered at The Elms Courtyard in Bromesberrow, UK, assists startups with essential administrative tasks such as payroll, accounts, HR, tax returns, and more, allowing entrepreneurs to focus on innovation and growth. Anglo Scientific has a comprehensive approach to supporting startups, managing tasks that often consume significant time for new businesses. Their portfolio includes companies that benefit from these streamlined services, enabling them to navigate the complexities of early-stage growth and investment readiness​.

Angular Ventures, founded in 2018 and headquartered in London with offices in Tel Aviv and New York, focuses on early-stage enterprise tech companies from Europe and Israel. The firm invests in deep tech sectors including AI, machine learning, developer tools, fintech, and infrastructure. They are known for backing companies with global ambitions and exceptional founding teams. Their portfolio includes companies like JFrog, a developer-focused software company that went public in 2020, and Forter, which provides e-commerce fraud prevention solutions. Aquant, another notable investment, uses AI to provide actionable service intelligence and was acquired by SmartBear. Dust Identity, which utilizes diamond dust for product authentication, recently raised a $40M Series B to expand into new markets. Reco focuses on business and productivity software, emphasizing data security and collaboration. Angular Ventures recently announced a $41M seed fund aimed at supporting enterprise and deep tech startups in Europe and Israel. This fund underscores their commitment to fostering innovation in these regions and sectors, ensuring that promising startups receive the necessary support to scale and succeed globally​.

ANIM is a global venture capital fund with a strong focus on investing in high-growth, innovative companies across various sectors. Based on available information, ANIM targets industries that leverage cutting-edge technologies, though specific sectors or portfolio companies were not clearly outlined. The fund appears to be driven by a mission to back transformative ventures that can scale rapidly, with a global perspective on markets and opportunities. ANIM's strategy seems to include early-stage investments, providing capital and strategic guidance to help startups grow. The fund likely looks for companies with strong leadership, scalability, and market potential. With its emphasis on growth, it’s reasonable to assume that ANIM plays an active role in the businesses it backs, offering more than just financial support. For entrepreneurs seeking investment, the fund might prioritize innovative solutions that have the potential for significant impact, both financially and in terms of market disruption.

Anorak Ventures, founded in 2016 and headquartered in San Francisco, is a seed-stage venture firm that focuses on investing in transformative technology and people. The firm primarily invests in pre-seed and seed-stage companies across various technology sectors, including artificial intelligence and machine learning (AI/ML), Internet of Things (IoT), robotics, and consumer tech. Anorak Ventures has invested in over 120 seed-stage technology companies, which now represent an aggregate market capitalization of $24.8 billion. Notable investments in their portfolio include companies such as Vantage Point, WeatherCheck, Orderful, Framework, Prisms VR, Better Health, and Marxent. They are dedicated to helping these companies achieve product-market fit and secure follow-on financing. The firm, led by Managing Partner Greg Castle, aims to support innovative startups by providing not just capital but also strategic guidance to help them scale and succeed in competitive markets​.

Anterra Capital is a venture capital firm that specializes in investments within the food and agricultural technology sectors. Founded in 2013, Anterra Capital has offices in Amsterdam and Boston and focuses on backing innovative companies that address critical challenges in agriculture, food production, and sustainability. Their portfolio includes notable investments such as Enko Chem, which develops novel crop protection products; ProducePay, a financial and data services platform for the fresh produce industry; and BiomEdit, which focuses on microbiome innovation for animal health. The firm manages over $450 million in assets and typically invests in Series A or B rounds, with initial checks ranging from $1 to $10 million. Anterra is committed to leveraging biotechnology and digital solutions to transform the food system, improve consumer health, and enhance the livelihoods of farmers. Their investment strategy emphasizes impact and sustainability, aligning with their goal to create a resilient and sustainable food system. Anterra Capital has raised significant funds, including a $260 million second Global Food and Agriculture Technology Fund, which continues to support biotech and digital innovations in the agrifood sector​.

Anthemis Group, founded in 2010 and headquartered in London, is a global investment platform dedicated to fostering innovation in the financial system. The firm focuses on fintech, insurtech, and related sectors, investing from seed to growth stages. Anthemis' portfolio includes notable companies such as Betterment, eToro, and Currencycloud. They also back innovative startups like Pipe, Weavr, and Atomic. With over 150 investments worldwide, Anthemis emphasizes diversity and inclusivity, with 23% of their portfolio companies founded by women and 40% led by women or BIPOC. Their commitment to diversity is further demonstrated through the Female Innovators Lab, which supports female founders in fintech across the UK and Europe. Anthemis recently closed multiple funds totaling over $700 million, expanding their support for fintech companies throughout their lifecycle. The firm also launched an ESG-focused SPAC to advance sustainable finance. Anthemis' thesis-driven approach leverages deep market insights to drive systemic, long-term change. Led by founder Amy Nauiokas and CEO Briana van Strijp, Anthemis is poised to continue its mission of reinventing finance through innovation, collaboration, and inclusivity, supporting the next wave of fintech innovation globally.

Antler is a globally renowned early-stage venture capital firm known as the "day zero investor," backing founders from the inception of their startups. With over 850 investments in 20+ countries, Antler has notable portfolio companies like Airalo, a global eSIM provider, and has recently raised a $60 million MENAP fund to further support startups in the Middle East, North Africa, and Pakistan region. Antler focuses on sectors including technology, fintech, and digital innovation, providing personalized coaching, co-founder matching, and follow-on funding. Key team members include Dr. Jonathan Doerr and Romain Assunção, leading regional activities from Riyadh and Duba

Anzu Partners is a venture capital firm founded in 2014, focusing on breakthrough industrial and life sciences technologies. Headquartered in Washington, D.C., with additional offices in Boston, San Diego, and Tampa, the firm manages over $1 billion in strategic assets across various funds and investment strategies. Anzu Partners has a robust portfolio of around 40 companies, including notable investments in e-Zinc, Framework, EnCharge, AM Batteries, and Arduino. The firm has also achieved significant exits, such as NUBURU and Ai-Media, highlighting its capability to support companies from early stages through to successful public offerings or acquisitions. Anzu specializes in three primary investment solutions: venture capital investments, debt and revenue-based investments, and Special Purpose Acquisition Companies (SPACs). The firm provides not just capital but also deep expertise in business development, market positioning, global connectivity, and operations, helping to drive the commercial success of its portfolio companies. The leadership team at Anzu Partners includes experienced professionals like Managing Partners David Michael, David Seldin, and Whitney Haring-Smith, who bring decades of combined experience in global investments and consultancy. This expertise is further supported by a dedicated team of technical and operational professionals.

Aonia Ventures is a Paris-based micro-VC firm founded in 2020 with roots in Switzerland, investing in 20 to 30 technology startups per year worldwide at seed and Series A stages. The firm deploys €100K to €250K per deal across healthtech, fintech, greentech, foodtech, wellness, and lifestyle — sectors where Aonia sees urgent problems and scalable solutions converging. A team of three partners runs the fund, maintaining a high-volume, hands-on investment cadence across Europe and the United States. With 55 portfolio companies and counting, Aonia has accumulated a track record that includes one unicorn — Alan, the French health insurance platform — and one public market exit via Field Trip Health and Wellness. These outcomes anchor the portfolio's credibility against a backdrop of broad, consistent early-stage deployment across multiple sectors and geographies. Aonia's model is deliberately high-frequency: by writing smaller checks across a large number of bets each year, the firm maximizes exposure to breakout outcomes while building a portfolio network with compounding cross-sector value. The fund's particular strength in health and wellness, combined with greentech and fintech coverage, reflects founders' growing interest in businesses that address large systemic challenges — a thesis Aonia has pursued since its founding and continues to refine with each cohort of investments.

Apax Partners is a leading global private equity advisory firm with a focus on inspiring growth and transforming businesses. Founded nearly 50 years ago, Apax has raised and advised over 30 funds, managing more than $77 billion in aggregate capital. The firm primarily invests in four sectors: Tech, Services, Healthcare, and Internet/Consumer. Apax operates several strategic funds, including Apax Global Buyout, which focuses on transformative growth in key sectors, and Apax Digital Growth, aimed at accelerating tech companies. Additionally, Apax Global Impact targets companies that deliver tangible societal and environmental benefits, while Apax Mid-Market Israel leverages local expertise to support growth in Israeli businesses. The firm also has Apax Credit and Apax Listed Private Equity strategies to provide a flexible investment approach across the capital structure​. Notable investments include Auto Trader Group, GlobalLogic, and Cole Haan, among others. Apax leverages its deep sector expertise and global network to drive operational excellence and digital transformation within its portfolio companies. The firm’s extensive experience and strategic focus have made it a prominent player in private equity globally, with offices in major financial hubs including London, New York, Hong Kong, and Tel Aviv​.

APEX Ventures is a venture capital firm based in Vienna, Austria, specializing in deep tech and medical technology startups. Founded in 2016, APEX Ventures invests in early-stage companies across Europe, with a focus on innovations in AI, quantum computing, automation, robotics, computer vision, space technology, and medical technology. The firm emphasizes backing startups with unique, defensible technologies that have the potential to disrupt and transform their respective industries​. In 2023, APEX Ventures partnered with Amadeus Capital Partners to launch the Amadeus APEX Technology Fund, which aims to raise €80 million to support deep tech startups primarily in the DACH region (Germany, Austria, and Switzerland). This fund focuses on seed and Series A investments, typically ranging from €1 million to €1.5 million. The partnership combines APEX’s local expertise and network with Amadeus’ extensive global experience in venture capital. APEX Ventures has a diverse portfolio, including companies like contextflow, ImageBiopsy Lab, and Mobius Labs. The firm is known for providing not just capital but also strategic support, leveraging their deep tech expertise and strong networks to help startups scale and succeed​.

Apollo Health Ventures is a transatlantic venture capital firm founded in 2016 and headquartered in Berlin, Germany. Co-founded and led by Managing Director Nils Regge, the firm's singular mission is to fund and co-build companies that target the root causes of aging and age-related diseases. Apollo focuses on breakthrough science in Alzheimer's disease, heart disease, cancer, sarcopenia, and frailty — with the ultimate goal of extending healthy human lifespan. The firm takes an active company-building role, frequently co-founding portfolio companies alongside scientists and entrepreneurs. Apollo leads rounds and has made approximately 13 investments across Seed and Series A stages, with seed rounds averaging $9.7 million and Series A rounds averaging $34 million. Notable portfolio companies include Auron Therapeutics, HAYA Therapeutics, Cleara Biotech, Cognito Therapeutics, and Aeovian Pharmaceuticals. The portfolio spans the United States and Europe, reflecting the firm's transatlantic orientation and its Bio Fund I structure. Apollo Health Ventures differentiates itself through its company-building model: the team does not passively invest in existing longevity companies but actively participates in their creation, recruiting scientists, shaping research strategy, and guiding early clinical positioning. This founder-in-residence approach concentrates portfolio expertise in a narrow therapeutic category and allows Apollo to shape the science from the earliest stages — well before most investors enter the conversation.

Applied Ventures is the venture capital arm of Applied Materials, based in Santa Clara, California. Since its establishment in 2006, the firm has focused on early-stage investments, primarily within deep technology sectors such as semiconductors, energy, advanced materials, and life sciences. Applied Ventures has a global reach, with investments spanning across North America, Europe, Asia-Pacific, and the Middle East. The firm is known for its flexibility, investing up to $100 million annually and actively participating in funding rounds ranging from $10 to $50 million. Its strategy emphasizes supporting startups with disruptive technologies by connecting them to Applied Materials' global ecosystem, which includes industry partners, supply chain resources, and technical expertise. Key portfolio companies include Ayar Labs (optical I/O technology), Rockley Photonics, and TXOne Networks, reflecting its focus on innovations that align with Applied Materials' core strengths in materials engineering and semiconductor technology​. The investment team is led by Anand Kamannavar, who serves as Global Head, alongside key figures such as Brad McManus, John Wei, and Rajesh Ramanujam, all based in Santa Clara. Applied Ventures is stage-agnostic, supporting both early and growth-stage startups as they scale globally, especially those involved in deep tech advancements.

Apposite Capital is a London-based venture capital firm specializing in the healthcare sector. Founded in 2006, the firm focuses on investing in innovative healthcare companies across the UK and Europe. Apposite Capital provides a mix of venture, development, and growth financing, along with buyout capital, primarily targeting companies that can significantly impact healthcare through improved services and technologies. Their investment strategy emphasizes supporting companies with scalable business models and strong growth potential. Apposite Capital has a track record of successful investments in healthcare services, medical devices, diagnostics, and digital health. The firm typically takes an active role in its portfolio companies, providing strategic guidance and leveraging its extensive network within the healthcare industry to drive growth and innovation. Apposite Capital's team brings a combination of operational, scientific, and financial expertise, allowing them to deeply understand and support the unique needs of healthcare businesses. They also focus on promoting best practices in environmental, social, and governance (ESG) and are committed to making a positive impact through their investments. Recent notable investments include companies like NIMGenetics, HCML, and Emblation, showcasing their commitment to advancing healthcare solutions and improving patient outcomes​.

Aqua-Spark, based in the Netherlands, is a global investment fund dedicated to sustainable aquaculture. Founded in 2013 by Mike Velings and Amy Novogratz, the fund aims to transform the aquaculture industry by promoting environmental and social sustainability alongside financial returns. Aqua-Spark's mission is to make the production of aquatic life such as fish, shellfish, and plants safe, accessible, and environmentally friendly. The fund manages around $450 million in assets and has invested in 24 companies across the aquaculture value chain, aiming to expand its portfolio to 50-60 companies. Some notable investments include eFishery, an Indonesian aquaculture tech startup, Calysta, a biotech company producing sustainable feed ingredients, and Wanda Fish, which is developing cultivated bluefin tuna. Aqua-Spark focuses on early-stage investments, typically at the Series A stage, and supports companies through to maturity. Their investments are chosen for their potential to generate significant environmental and social impacts while delivering solid financial returns. The fund has a diverse investor base of around 300 investors from over 25 countries.

Aquarius Equity is a UK-based venture capital firm with a strong focus on early-stage investments in high-growth companies, particularly those located in the North of England. The firm, established to bridge the venture capital gap in this region, is dedicated to supporting innovative startups that have the potential to scale significantly. Their latest fund, the Aquarius Origin Fund, targets investments of up to £750,000, focusing on sectors like biotechnology, life sciences, and technology. Aquarius Equity's investment strategy emphasizes scalability and sustainability, with a particular interest in companies that align with the UN Sustainable Development Goals. They seek out companies with proven business models and significant growth potential, especially those that have already secured investment from industry-recognized investors. The firm also encourages investments from private individuals through Self Invested Personal Pension (SIPP) schemes, allowing them to invest in early-stage companies traditionally dominated by institutional funds. Aquarius Equity is not just a financial backer but also an active partner, providing strategic support to help startups achieve their growth ambitions. The firm’s commitment to innovation and sustainability positions it as a key player in the venture capital landscape, particularly in the UK’s underserved Northern regions.

Aramco Ventures is the corporate venture capital arm of Saudi Aramco, one of the world’s largest integrated energy and chemicals companies. Established in 2012, the fund has grown significantly, recently receiving an additional $4 billion, bringing its total capital to $7.5 billion. This expansion supports Aramco's long-term strategy of investing in technologies critical to energy transition and sustainability. Aramco Ventures operates through several specialized funds, including its Prosperity7 and Sustainability Fund, focusing on sectors such as carbon management, hydrogen, renewables, AI, and advanced materials. The firm has made over 140 investments globally, backing companies like Promethean Particles and Seeq that align with its strategic goals of advancing low-carbon and innovative technologies. The fund is headquartered in Dhahran, Saudi Arabia, and led by CEO Mahdi Aladel. It actively seeks out companies that can contribute to the global energy transition, emphasizing technologies that offer scalable solutions to the challenges facing the energy sector today​.

Aravis is a private equity firm based in Zurich, Switzerland, founded in 2001 by Jean-Philippe Tripet. The firm focuses on high-tech growth investments, primarily in the biotech, creative and digital, and industrial high-tech sectors. Aravis has sponsored multiple fund vintages and has deployed over USD 400 million across four funds. Aravis Growth I LP, their latest initiative, targets investments in established, innovative Swiss and European companies with significant growth potential. This fund aims to fill the gap in growth capital in the region by offering strategic advice, access to networks, and capital to accelerate companies through their growth phases​. The team at Aravis is composed of experienced professionals from various backgrounds, including finance, industry, and technology, providing a wealth of knowledge and expertise to support their portfolio companies. Their investment approach also integrates ESG criteria, aligning with several UN Sustainable Development Goals (SDGs).

ARAX Capital Partners, founded in 2007 and based in Vienna, Austria, is a venture capital firm that focuses on early-stage investments across the life sciences and technology sectors. They are particularly invested in Austrian ventures, targeting young, innovative companies, especially those with patentable technology. ARAX is committed to fostering the growth of startups in these fields by providing significant strategic and financial support. The firm's notable investments include Calyxha Biotechnologies, EveliQure Biotechnologies, and Panoptes Pharma, showcasing their emphasis on biotech and life sciences. Additionally, they have invested in technology companies like The MoonVision and crystalsol, a renewable energy company​​. ARAX Capital Partners generally participates in funding rounds ranging from $1 million to $9 million and has made 41 investments to date. They typically lead rounds, indicating their active role in shaping the growth trajectories of their portfolio companies​​. The team at ARAX is led by experienced partners such as Christian Tiringer, Beatrix Schuberth, and Thomas Cimbal, who bring extensive expertise in venture capital and entrepreneurship to the firm​​. This leadership helps ARAX maintain a strong network and high-quality deal flow, positioning them as a key player in Austria’s venture capital landscape. For startups, ARAX Capital Partners is a valuable partner, particularly for those in the early stages of development, looking for both capital and strategic guidance to scale their innovative solutions in the biotech and technology sectors​.

Arbor Ventures is a Singapore-based fintech venture capital firm founded in 2013 by Melissa Guzy and Wei Hopeman. With $519 million in assets under management across eight funds — including Fund I at $125 million and Fund II at $235 million — Arbor focuses on companies leveraging advanced technology to transform financial services. The firm's fintech mandate is broadly defined, encompassing regtech, insurtech, cybersecurity, AI, and blockchain across North America, Europe, and Asia. The firm leads rounds and has made 85 investments, backed by a team of 15 including seven partners. Arbor's track record is among the strongest in Asian venture: six portfolio unicorns including Tabby and Akulaku, two IPOs — Grab on NASDAQ at a $40 billion market cap in 2021 and Lufax on the NYSE — and 11 acquisitions including EverC, acquired by G2 Risk Solutions. Additional portfolio companies include Fundbox, Paidy, and AppliedAI. The firm invests primarily at Seed and Series A, deploying $3 million to $20 million per company, with the largest concentration of investments in the United States followed by Israel. Arbor Ventures built its edge through cross-border network density: connecting entrepreneurs, corporations, and capital across Asia, the US, and Europe before most fintech-focused funds saw the category as global. Guzy and Hopeman's combined expertise in financial services technology and international market-building gives portfolio companies an accelerated path to geographic expansion that few early-stage investors in fintech can match.

Archimed Group, founded in 2014 and headquartered in Lyon, France, is a leading private equity firm specializing in the healthcare sector. The firm manages around €8 billion in assets and is focused on investing in small to midsize companies across seven key healthcare sectors, including Biopharma, MedTech, and Healthcare IT. Archimed’s strategy involves acquiring majority stakes in companies and working closely with them to accelerate growth, drive innovation, and expand internationally. Archimed has a strong track record, with its funds consistently ranking in the top decile for performance. The firm’s latest fund, MED Platform II, closed at €3.5 billion in 2023, making it the largest healthcare-only private equity fund raised by a European-based firm. This fund is primarily focused on mid-cap companies in Europe and North America, aiming to support healthcare leaders in scaling their operations through strategic acquisitions and capacity expansions. Archimed’s commitment to impact investing is evident through its alignment with sustainable development goals and its EURÊKA Foundation, which supports healthcare-related charitable initiatives. The firm’s unique blend of financial, medical, and operational expertise positions it as a key player in the global healthcare investment landscape.

Architect Partners Ventures is the direct investment arm of Architect Partners (AP), the leading crypto mergers and acquisitions and strategic financing advisory firm, founded in 2009 by Eric Risley and co-led with Steve Payne. The broader firm has advised on major transactions including Securitize's acquisition of Velocity Capital Markets, Polygon Labs' intended acquisitions of Coinme and Sequence, and Champ Titles' $18 million Series C. The ventures unit extends this advisory platform into direct early-stage investing in the crypto and fintech ecosystem. The fund deploys $10K to $100K — with a sweet spot of $25K — at pre-seed and seed stages globally across Web3 and blockchain, digital assets, fintech, data analytics, advertising technology, and marketplaces. With 14 investments and a distributed team across the San Francisco Bay Area, New York, and Southern California, Architect Partners Ventures occupies a niche as a seed investor with direct access to crypto M&A flow and strategic intelligence. The firm publishes widely-followed research including crypto M&A alerts and sector topology reports. The ventures arm's primary advantage is informational: operating at the intersection of M&A advisory and direct investing gives the team unusual visibility into acquirer appetites, strategic gaps, and valuation benchmarks across the crypto ecosystem. Founders who take capital from Architect Partners gain not just a check but a firm that understands how their company might ultimately be acquired, licensed, or merged — and is actively working those relationships on their behalf.

Arcus Ventures is a New York-based venture capital firm founded in 2007 by Steven L. Soignet and James B. Dougherty, dedicated exclusively to oncology-focused life sciences companies. The team brings deep experience across clinical and academic medicine, drug development, hospital management, healthcare consulting, and private equity — a multi-disciplinary foundation that informs both investment selection and portfolio support. The firm closed a cancer-focused fund at $45 million in August 2014. Arcus leads rounds and targets three opportunity types: innovative biopharmaceuticals or drug delivery platforms in development, medical device companies approaching pre-marketing approval, and commercial-stage service businesses with positive revenue. Check sizes of $1 million to $5 million are deployed at Series A and Series B stages across North America and Europe. Notable portfolio companies include Cleave Therapeutics, Exosome Diagnostics, XTuit Pharmaceuticals, TRACON Pharmaceuticals, T2 Biosystems, and Vascular Pathways, collectively spanning drug discovery, diagnostics, biopharmaceuticals, and medical devices. Arcus Ventures' singular sector focus is its defining characteristic: by investing only in oncology, the firm develops a depth of scientific and commercial judgment that generalist healthcare funds cannot replicate. Soignet and Dougherty's combined clinical and entrepreneurial backgrounds allow them to evaluate not only the science but the regulatory and commercial pathway — providing portfolio companies with guidance that is specific, experienced, and directly applicable to the challenges of bringing cancer therapies to market.

Aleph VC, founded in 2013 and based in Tel Aviv, specializes in early-stage investments, primarily partnering with Israeli entrepreneurs. With $850 million under management, Aleph focuses on building meaningful companies and impactful global brands across various sectors, including fintech, digital health, cybersecurity, AI, and machine learning. Notable investments by Aleph include Lemonade, a full-stack global insurance company, and Melio, which provides digital payment tools for small businesses. Other prominent portfolio companies include Nexar, a dashcam and edge-AI platform for better driving, and Freightos, a digital freight marketplace. The firm has also seen significant exits, such as the acquisition of Raftt and the public offering of Freightos​. Aleph typically invests between $2 million and $12 million in seed and pre-seed stages, focusing on innovative companies poised for global expansion. The team, led by co-founders Michael Eisenberg and Eden Shochat, leverages their extensive network and expertise to provide strategic guidance and access to global markets, aiming to create long-term value for their portfolio companies.

Arix Bioscience is a global venture capital firm based in London, specializing in biotechnology investments. Founded in 2016, Arix focuses on backing early-stage companies that are developing breakthrough treatments and technologies in the life sciences sector. Their investment strategy targets ventures from late pre-clinical to clinical stages, emphasizing a diversified portfolio to mitigate risks inherent in biotech investments​. The firm has built a robust portfolio that includes companies like Autolus, a developer of CAR-T cell therapies for cancer, and Disc Medicine, which focuses on treatments for hematologic diseases. Arix has also been involved in significant financing rounds, such as the $50 million Series B for Evommune and Ensoma, highlighting their role in advancing innovative biotech startups. Arix operates a permanent capital model, allowing it to support its portfolio companies through market fluctuations without being bound by strict exit timelines. This approach enables them to provide sustained support to their investments, which is critical in the high-risk, high-reward biotech sector.

Arkin Bio Ventures is a Tel Aviv-based life sciences venture capital firm founded in 2016 as part of Arkin Capital, a diversified global investment manager with over $2 billion in assets under management across twelve funds. Arkin Bio operates as a joint venture between Phoenix Group (49%) and Arkin Holdings (51%), and has raised three funds: Fund I in 2016, Fund II at $140 million in 2020, and Fund III at $100 million closed in January 2026 — bringing total life sciences AUM above $600 million. Managing Partner Dr. Pini Orbach and Partner Alon Lazarus lead a team of ten, including four partners. The firm leads rounds and invests $3 million to $20 million per company at early and mid-stage in biotech companies developing therapies in immunotherapy, cancer, metabolism, microbiome, autoimmune diseases, and drug delivery. With 27-plus investments and more than 20 successful exits through IPOs and acquisitions, Arkin Bio has backed UroGen Pharma, Keros Therapeutics, Bluejay Therapeutics, cCAM Biotherapeutics, Hi-Bio, and ImmPACT Bio, among others. Arkin Bio's partnership with Phoenix Group provides co-investment capacity that extends individual deal capability and supports portfolio companies through multiple rounds. The team works closely with founders on biological strategy, translational planning, and clinical positioning — going well beyond check-writing to serve as active scientific and commercial advisors during the most capital-intensive stages of drug development.

Arkley Brinc VC is a venture capital firm based in Warsaw, Poland, that focuses on early-stage investments in hardware-enabled startups, particularly in IoT, MedTech, and smart manufacturing sectors. The firm was established as a joint initiative between Arkley, a European pioneer in hardware investments, and Brinc, a global accelerator known for its deep connections in China’s manufacturing hubs. This partnership allows Arkley Brinc to offer startups not only capital but also a wealth of resources for product development, manufacturing, and global distribution. With a fund size of $15 million, Arkley Brinc invests up to $1 million per company, supporting them from the prototype stage through to IPO. The firm’s investments are concentrated in Poland and across Europe, leveraging its strategic networks to help startups scale effectively. Arkley Brinc has a strong track record, with over 50 projects supported and several successful exits and IPOs. The firm’s team consists of serial entrepreneurs and finance professionals with extensive experience in launching and scaling technology businesses. The Arkley Launchpad program is another key initiative, offering a highly individualized acceleration program designed to raise successful funding rounds and drive operational success. This program is tailored to the specific needs of each startup, providing access to a network of partners in prototyping, manufacturing, sales, and investment.

Armilar Venture Partners is a leading venture capital firm based in Lisbon, Portugal, with a strong international presence. Since its founding in 2000, Armilar has focused on early-stage technology-based companies, particularly in sectors where data, digitization, and connectivity are central. Notable investments include OutSystems, Feedzai, and Vawlt, showcasing their commitment to companies driving digital transformation. Armilar specializes in deep-tech investments, supporting startups that leverage cutting-edge technology to address significant societal challenges. They have a hands-on approach, providing not only capital but also strategic guidance to help their portfolio companies scale effectively. Their investment strategy includes focusing on companies with strong intellectual property and significant market potential, often leading funding rounds to ensure their startups have the resources needed for success. Geographically, while Armilar has a strong focus on Portugal, they are open to investing globally, demonstrating flexibility in finding and supporting the best opportunities regardless of location. Their investment strategy is characterized by patience and long-term support, often leading funding rounds and staying engaged through critical growth phases. The firm has a notable team, including Joaquim Rodrigues, the founder, and managing partners like Nuno Leite and Pedro Santos. These leaders bring extensive experience and a deep understanding of both technology and market dynamics, ensuring they can provide valuable support to their portfolio companies.

Artesian Investments, founded in 2004 by Jeremy Colless, Matthew Clunies-Ross, and John McCartney, is a global alternative investment management firm specializing in venture capital, public and private debt, and impact investment strategies. Based in Sydney, the firm has expanded its reach with offices in Melbourne, Adelaide, Shanghai, Jakarta, Singapore, London, and New York​​. Artesian's notable investments include Instaclustr, PouchNATION, and Regrow Ag. They are particularly active in the Asia-Pacific region, managing over $1.22 billion in assets and boasting more than 600 startup investments​ (Artesian)​. Their investment strategy focuses on early-stage ventures across various sectors, including technology, agrifood, medtech, and AI. Artesian also offers a unique "Venture Capital as a Service" (VCaaS) platform, providing customized investment solutions to corporations, government, and family offices​. The firm places a strong emphasis on ESG (Environmental, Social, and Governance) criteria and impact investing, aiming to deliver sustainable returns while addressing critical global challenges. Artesian is a certified B Corp, underscoring their commitment to positive social and environmental impact. Key team members include Jeremy Colless (CEO), Matthew Clunies-Ross (CIO), and Luke Fay (Partner, Australian Venture Capital). Their diversified team spans multiple continents, bringing extensive expertise and a global perspective to their investment activities

Arthur Ventures, established in 2008 and headquartered in Minneapolis, Minnesota, focuses on investing in early-stage B2B software companies across the U.S. and Canada. They emphasize backing startups located outside Silicon Valley, promoting innovation and growth in diverse regions. Arthur Ventures' portfolio includes a variety of successful companies. Notable investments feature DataCamp, an online data science training platform; Protenus, which offers patient data protection; and ThreatLocker, a zero-trust endpoint security solution. Other significant portfolio companies include Jane.app, a practice management software for health and wellness clinics, and CertifID, a network management software company. The firm has made over 102 investments and has seen 18 exits, with companies like Ionic and TINYpulse achieving successful outcomes. Arthur Ventures focuses on sectors such as SaaS, cybersecurity, fintech, and healthcare IT, providing capital and strategic support to help early-stage companies grow and succeed.

Asahi Kasei Ventures — formally Asahi Kasei Corporate Venture Capital — is the CVC arm of Asahi Kasei Corporation, a diversified Japanese conglomerate with revenues exceeding $20 billion across its Materials, Homes, and Health Care divisions. Established in 2008 in Tokyo and operating from Silicon Valley since 2011, with additional offices in Menlo Park and Boston, the fund invests in innovative startups strategically aligned with Asahi Kasei's long-term business development. General Manager Takashi Morishita has guided the fund since inception, personally involved in investments in 30-plus startups. The firm has invested in 53-plus companies across the United States, Europe, China, and Japan, averaging two new investments annually. Checks range from $1 million to $10 million at seed through Series B stages. Focus areas include healthcare and digital health, advanced materials, IoT, clean technology, energy storage, hydrogen, and biopharmaceuticals. The most recent investment was in Glycomine at Series C in April 2025. The fund's Care for Earth investment framework extends the mandate to environmental startups in sustainability and carbon neutrality. Portfolio companies gain access to Asahi Kasei's extensive research capabilities, manufacturing infrastructure, and global commercial network — advantages that have resulted in multiple strategic collaborations and two acquisitions for the parent company. The fund's long-term orientation and corporate backing allow it to support companies through extended development cycles that financial-only investors may not sustain.

Ascension Ventures is a strategic healthcare-focused venture capital firm based in St. Louis, Missouri. Launched in 2001 by Ascension, it manages over $1 billion in assets across five funds. The firm strategically invests in early to late-stage companies within healthcare services, health technology, and medical devices. Its unique approach connects more than 450 healthcare providers, creating an ecosystem that enables startups to directly engage with health system executives, driving solutions that address complex healthcare challenges. Ascension Ventures’ portfolio includes companies like Olive (an AI platform for healthcare administration), EBR Systems, and GetWellNetwork, reflecting its emphasis on technology that enhances clinical outcomes, patient experience, and operational efficiency. The firm typically invests between Series A and B rounds, with capital sizes ranging from $10 to $20 million per company, often seeking board seats or observer rights to guide their portfolio firms. The firm is distinguished by its close ties to 13 major health systems, which represent a network of over 580,000 healthcare professionals. This strategic positioning allows Ascension Ventures not only to provide funding but also to facilitate partnerships and scale innovations that improve healthcare delivery across the United States.

Asimov Ventures is an early-stage venture capital firm with offices in New York City and Palo Alto. The firm focuses on investing in cutting-edge technologies such as 3D printing, robotics, and advanced computing. Asimov Ventures seeks to partner with visionary entrepreneurs dedicated to transforming their industries through innovative solutions. Notable investments by Asimov Ventures include Particle3D, which specializes in 3D-printed bone implants, and Kadena, a blockchain technology company. The firm also invests in various other sectors, including healthcare, e-commerce, and augmented reality, reflecting their broad interest in transformative technologies​. Asimov Ventures typically participates in funding rounds with other notable investors, providing capital and strategic support to help startups scale and succeed. Their investment strategy emphasizes early-stage companies with strong intellectual property and commercial potential​.

Astanor Ventures, founded in 2017 by Eric Archambeau and George Coelho, is a Brussels-based venture capital firm specializing in sustainable agrifood technologies. The firm focuses on investing in early-stage, mission-driven companies that address significant social or environmental issues within the agrifood value chain. This includes sectors like regenerative agriculture, bioeconomy, and climate-positive solutions. Astanor recently closed its second venture fund at €360 million, bringing its total assets under management to €800 million. This fund will support innovative solutions aimed at transforming the global food system to be more sustainable and resilient​. The firm boasts an extensive network of entrepreneurs, experts, scientists, and policymakers, which helps identify and nurture groundbreaking technologies. Notable investments include companies that advance autonomous electric agricultural machinery, high-functioning proteins, and genomic sequencing for sustainable food production.

Astellas Venture Management (AVM) is the wholly-owned corporate venture capital arm of Astellas Pharma, one of the world's leading pharmaceutical companies. Founded in 2005 and headquartered in South San Francisco, AVM has provided equity investments to private, early-stage companies developing therapeutic programs and platform technologies for over twenty years. The investment thesis is explicitly strategic: AVM targets science that enhances the Astellas R&D pipeline or catalyzes new directions in discovery research, with the team's Pharma View serving as both a selection lens and a support framework. AVM has invested in 61 companies across 104 total investment rounds, deploying $3 million to $20 million per company at seed through Series B stages. Series A is the most active stage, with 19 investments averaging $33.8 million in round size. Notable current portfolio companies include Solu Therapeutics, Syntax Bio, PhoreMost, and Somite. The most recent investment was in Solu Therapeutics in April 2025, and the most recent exit was Orna Therapeutics in February 2026. A team of eight, including three partners and one principal, spans the US and Japan. AVM's principal value to portfolio companies is its deep pharmaceutical industry expertise and the pathway it opens to Astellas Pharma: strategic licensing dialogues, research collaborations, and potential acquisitions that purely financial investors cannot facilitate. For early-stage biotech founders, AVM's Pharma View means receiving guidance from investors who understand drug development not as outsiders but as participants in the global pharmaceutical system.

Aster Capital, established in 2000 and based in Paris, is a venture capital firm specializing in Climate Tech investments. The firm focuses on sectors such as energy, mobility, and industry, supporting startups at various stages of development. Aster Capital manages around €500 million in assets and operates globally with offices in Paris, San Francisco, and Tel Aviv. Key investments by Aster include companies like ekWateur, an energy supplier accelerating the energy transition; Betterway, a pioneer in employee mobility solutions; and Iceotope, specializing in liquid cooling technologies for data centers. These investments reflect Aster’s commitment to supporting innovative solutions that contribute to carbon neutrality. Aster recently raised €240 million to invest in energy transition and future mobility projects, underscoring their dedication to driving significant environmental impact through technology. The firm’s strategy involves not only financial investment but also providing extensive support through their "Business Hub" approach, which facilitates business opportunities and partnerships for their portfolio companies​.

AstraZeneca is a leading global biopharmaceutical company with a strong focus on oncology, biopharmaceuticals, and rare diseases. They are committed to discovering, developing, and delivering innovative medicines that transform the lives of patients worldwide. AstraZeneca's oncology portfolio is particularly noteworthy, with a significant emphasis on creating groundbreaking cancer treatments. Their strategy includes leveraging various scientific platforms such as antibody-drug conjugates (ADCs), radioconjugates, and T cell engagers. Recent high-profile deals include collaborations with Daiichi Sankyo for ADCs and the acquisition of Neogene Therapeutics to enhance their T cell receptor therapy capabilities​​. In addition to oncology, AstraZeneca has a robust pipeline in biopharmaceuticals aimed at addressing chronic diseases and enhancing long-term health outcomes. They are also advancing treatments for rare diseases, expanding their reach globally to ensure broader access to their innovative therapies​​. AstraZeneca's business development approach is integral to their growth, focusing on strategic alliances and partnerships. This includes collaborations with companies like Tempus for AI-enabled precision medicine and various biotech firms to accelerate advancements in areas like epigenetics and undruggable targets​​. The company emphasizes a culture of innovation, diversity, and sustainability, aiming to make a significant impact on global health while maintaining environmental responsibility through initiatives like Ambition Zero Carbon​.

Astutia Ventures is a Munich, Germany-based venture capital firm founded in 2006 by Benedict Rodenstock, focused on innovative European startups across three thematic areas: smart cities, the future of commerce, and digital lifestyle. The firm invests at seed and Series A stages, writing checks of $500K to $3 million, with a portfolio of 30 companies built over nearly two decades of active European investing. The team of four, including two partners, operates alongside an advisory practice — Astutia Advisory — that extends the firm's influence into venture capital consulting. Portfolio companies include Commercetools, a modern commerce infrastructure platform; Mister Spex, a leading European eyewear e-commerce company; Dreamlines, a cruise booking platform; Koloma, an energy company; and 99chairs, an interior design marketplace. The firm frequently co-invests with HTGF (High-Tech Gründerfonds) and other established European early-stage funds, indicating its position within the core Munich and broader German venture network. Astutia's thematic focus on smart cities, commerce, and lifestyle technology has proven durable over multiple market cycles, covering both consumer-facing and enterprise applications within European markets. Benedict Rodenstock's Munich business network gives portfolio companies access to the Bavarian industrial and commercial ecosystem — a geography that is both one of Europe's most economically productive and one of the less saturated by venture capital compared to Berlin or London. The firm's selective approach and deep regional roots produce a portfolio that is distinctive rather than generic.

FoodLabs, founded in 2015 and based in Berlin, Germany, is a prominent venture capital firm dedicated to investing in innovative startups within the food, health, and sustainability sectors. The firm supports companies aiming to revolutionize how we produce, consume, and think about food, with a mission to create sustainable and healthy solutions for the future. FoodLabs has made a significant impact with its diverse portfolio, which includes companies like ChefCoco, a personalized weekly menu service, and Van Heron Labs, which focuses on biotechnology. The firm has been an early investor in some of the most influential European FoodTech startups, such as Infarm, Meatable, Mushlabs, and Sanity Group. These investments span across various stages, from pre-seed to series B and beyond, demonstrating FoodLabs' commitment to nurturing startups through their growth journey. The team at FoodLabs, led by founder Christophe Maire and managing director Patrick Noller, combines deep industry expertise with a strong network to provide strategic support and resources to their portfolio companies. They are particularly focused on sectors like synthetic biology, climate resilience, and health, aiming to address some of the world's most pressing challenges.

Atlantic Labs, based in Berlin, is a prominent early-stage venture capital firm that supports mission-driven founders across Europe. Founded in 2013, the firm has a focus on investing in transformative technology sectors such as climate tech, digital health, future of work, AI and data, industrial automation, mobility and logistics, fintech, and proptech. Atlantic Labs typically invests at the pre-seed stage, with investment sizes ranging from €25,000 to €5 million or more. They have backed over 215 companies, including notable names like SoundCloud, GetYourGuide, Clue, Vimcar, and Cazoo. The firm emphasizes a hands-on approach, providing not only capital but also strategic guidance and access to a robust network of industry experts to help their portfolio companies grow and succeed. The firm's portfolio reflects its diverse focus areas, supporting companies that aim to redefine various industries through innovative solutions. Examples include digital health companies like Clue, AI and data startups such as Mobius Labs, and mobility ventures like GetYourGuide and Cazoo. Atlantic Labs is led by a team of experienced investors and operators who are committed to supporting entrepreneurs throughout their entire journey. This commitment to fostering innovation and growth has established Atlantic Labs as a key player in the European venture capital landscape.

Atlantic Vantage Point (AVP), based in Paris, is an independent global investment platform with more than $2.7 billion in assets under management. Originally founded in 2016 as the corporate venture capital arm of AXA — one of the world's largest insurance groups — the firm completed a management buyout from AXA in 2024 to become a fully independent entity, with AXA remaining as an anchor limited partner. AVP leads rounds across Europe and North America, deploying from its flagship €1.5 billion AVP Growth I fund. The firm has made 94 investments across enterprise software, fintech, insurtech, digital health, and cybersecurity, backing businesses from early growth through to late stage. With typical checks ranging from $10 million to $100 million, AVP operates as a transatlantic platform combining deep local expertise in both European and North American markets. Its heritage in insurance and financial services provides portfolio companies with a distinctive strategic lens and access to industry relationships built over years within the AXA ecosystem. AVP's investment approach emphasizes strategic guidance alongside capital, leveraging its position at the intersection of European and US technology markets to help portfolio companies scale across both geographies. The firm's scale, sector expertise, and ability to support companies across multiple funding rounds distinguish it from single-geography growth investors. Its 2024 independence marks a new phase — one defined by broader LP relationships while retaining the institutional depth of its AXA origins.

Atlantis Ventures is a Munich, Germany-based pre-seed and seed stage venture capital firm founded in 2021. The firm invests in tech and software companies across the DACH region, the Nordics, and the United Kingdom, with a particular focus on SaaS, deep tech, and sustainability. Operating with a cross-border team split between Germany and India, the firm gives portfolio companies access to both European and South Asian markets and talent pools. Since its founding, Atlantis has invested in 22 companies, with active deployment continuing — including one new deal in the most recent 12 months. Checks range from under $100,000 to $500,000, targeting outlier founding teams at the earliest stage of company formation. The firm has built a portfolio spanning software, AI, and climate-focused ventures, reflecting the intersection of technology and impact that defines its thesis. Atlantis Ventures operates with a team-first investment philosophy, summarized by its tagline "Building the future, one extraordinary team at a time." Rather than filtering primarily by market size or product maturity, the firm prioritizes the quality, ambition, and composition of founding teams. This approach reflects a conviction that exceptional people building in important categories produce durable outcomes, and that the pre-seed stage is precisely where investor support creates the most leverage. The firm's lean structure keeps it close to founders throughout the earliest formative period.

Atlas Venture is a leading venture capital firm specializing in early-stage investments in biotechnology and life sciences. Founded in 1980 and based in Cambridge, Massachusetts, Atlas Venture has built a robust portfolio by focusing on groundbreaking biotech innovations. The firm has raised multiple funds, including their most recent Fund XIII at $450 million, which emphasizes their commitment to fueling biotech startups from seed stage through to successful exits​. Notable investments in their portfolio include companies like Intellia Therapeutics, Kymera Therapeutics, and Ikena Oncology. These investments highlight Atlas Venture's dedication to developing therapies that address significant unmet medical needs, particularly in oncology and genetic disorders. Intellia Therapeutics, for instance, is renowned for its gene-editing technologies, while Kymera Therapeutics focuses on protein degradation to treat diseases. Atlas Venture has achieved numerous successful exits, such as the acquisitions of IFM Therapeutics by Bristol-Myers Squibb and Novartis, and the IPO of Generation Bio. These exits underscore the firm’s strategic capability in identifying and nurturing high-potential biotech startups to maturity. The firm is led by a team of experienced partners, including Jean-Francois Formela, Jason Rhodes, and David Grayzel, who bring a wealth of expertise in venture capital and life sciences. This team collaborates closely with entrepreneurs to provide not just capital but also strategic guidance and operational support, leveraging their extensive network within the biotech industry. For startups aiming to partner with Atlas Venture, it is crucial to present innovative solutions with strong scientific foundations and clear pathways to address significant medical challenges. The firm values startups that demonstrate potential for substantial clinical impact and scalability within the healthcare sector.

AtmosClear Investments is a Lausanne-based venture capital firm dedicated to accelerating the clean-tech revolution by investing in disruptive technologies that drive sustainability. Established in 2001, AtmosClear focuses on sectors like renewable energy, water purification, sustainable agriculture, and smart city infrastructure. Their diverse portfolio includes companies working on innovative solutions such as large-scale solar and wind energy projects, energy storage, recycling systems, and biofuels, with investments across Europe, particularly the UK and Switzerland. One of their notable ventures is Close the Loop, a recycling company specializing in repurposing ink cartridges, and they have also managed major solar installations in the UK, totaling over 30 MW. The firm’s mission is to generate both financial returns and positive environmental impact, emphasizing the reduction of harmful pollutants like microplastics and greenhouse gases. They support companies at various stages, from early startups to more mature businesses in need of growth capital​. AtmosClear’s team is led by experienced professionals with decades of expertise in finance and private markets. Founder Henry Sykes and his team leverage their deep knowledge to identify opportunities that align with their sustainability ethos. The firm’s global reach is underscored by investments in multiple continents, and they continue to seek out promising clean-tech entrepreneurs who share their vision of a more sustainable future. With a strong emphasis on long-term ecological benefits, AtmosClear is setting a new standard for responsible, impactful investing in the clean-tech space.

Atomico, founded in 2006 by Skype co-founder Niklas Zennström, is a leading venture capital firm based in London, with additional offices in Paris, Berlin, and Stockholm. The firm focuses on Series A and beyond investments in disruptive technology companies globally. Atomico's notable investments include Klarna, Truecaller, Lime, Hinge Health, and Rovio, which highlight their strong presence in fintech, healthcare, consumer tech, and gaming sectors. Atomico's investment strategy centers around partnering with mission-driven European founders, providing them with not just capital but also extensive operational support through their Growth Acceleration Team. This team assists with scaling operations, strategic planning, and navigating complex market dynamics. Their typical investment range is from $10 million to $50 million, and they often lead rounds, ensuring significant influence in their portfolio companies' trajectories. The firm is known for its diverse team and deep industry expertise. Key figures include Niklas Zennström, CEO and Partner; Chris Barnes, COO; and Thomas Wehmeier, Partner and Head of Insights, all based in London. This diverse leadership team brings a wealth of experience from various sectors, enhancing their ability to support and scale innovative startups. For startups looking to engage with Atomico, it's crucial to showcase innovative solutions with a potential for significant market impact. The firm is particularly interested in technology-driven companies that can leverage shifts in consumer behavior and technological advancements.